On Tuesday, Exact Sciences Corp. (NASDAQ: EXAS) opened higher 0.42% from the last session, before settling in for the closing price of $69.35. Price fluctuations for EXAS have ranged from $40.62 to $79.62 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 43.88% over the past five years. Company’s average yearly earnings per share was noted 17.61% at the time writing. With a float of $181.98 million, this company’s outstanding shares have now reached $184.77 million.
Let’s look at the performance matrix of the company that is accounted for 6600 employees. In terms of profitability, gross margin is 72.3%, operating margin of -7.26%, and the pretax margin is -6.59%.
Exact Sciences Corp. (EXAS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Exact Sciences Corp. is 1.51%, while institutional ownership is 97.53%. The most recent insider transaction that took place on Oct 08 ’24, was worth 65,030. In this transaction EVP, GM, Precision Oncology of this company sold 929 shares at a rate of $70.00, taking the stock ownership to the 12,758 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Officer proposed sale 929 for $70.00, making the entire transaction worth $65,030.
Exact Sciences Corp. (EXAS) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted 0 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.48) by 0.48. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.61% per share during the next fiscal year.
Exact Sciences Corp. (NASDAQ: EXAS) Trading Performance Indicators
Check out the current performance indicators for Exact Sciences Corp. (EXAS). In the past quarter, the stock posted a quick ratio of 1.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Exact Sciences Corp. (EXAS)
Exact Sciences Corp. (NASDAQ: EXAS) saw its 5-day average volume 1.14 million, a negative change from its year-to-date volume of 2.54 million. As of the previous 9 days, the stock’s Stochastic %D was 28.91%. Additionally, its Average True Range was 2.19.
During the past 100 days, Exact Sciences Corp.’s (EXAS) raw stochastic average was set at 92.51%, which indicates a significant increase from 52.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.62% in the past 14 days, which was lower than the 56.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $66.14, while its 200-day Moving Average is $58.80. Nevertheless, the first resistance level for the watch stands at $70.26 in the near term. At $70.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $71.70. If the price goes on to break the first support level at $68.82, it is likely to go to the next support level at $67.99. The third support level lies at $67.38 if the price breaches the second support level.
Exact Sciences Corp. (NASDAQ: EXAS) Key Stats
There are currently 184,770K shares outstanding in the company with a market cap of 12.87 billion. Presently, the company’s annual sales total 2,500 M according to its annual income of -204,150 K. Last quarter, the company’s sales amounted to 699,260 K and its income totaled -15,810 K.
